Findings reveal different biological responses after Paclitaxel treatment in coronary lesions, suggesting implications for DCB therapy.
Paclitaxel-coated balloon treatment was associated with favorable outcomes, including LLE and a reduction in maxLCBI₄mm, irrespective of lipid burden. However, the mechanisms underlying LLE may differ between lipid-rich and non-lipid-rich lesions, suggesting potential heterogeneity in biological responses to DCB therapy.
No takes yet. Share an insight, caveat, or question.
Matsuhiro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: